Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Entresto (sacubitril/valsartan) and Farxiga (dapagliflozin) are both medications used to help manage heart failure, but they belong to different medication classes and have distinct uses. Entresto is an angiotensin receptor-neprilysin inhibitor (ARNI) specifically approved for treating heart failure in people ages 1 year and older. It combines two medications, sacubitril and valsartan, to help relax blood vessels and improve heart function. Farxiga, on the other hand, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor primarily used to lower blood sugar in people with Type 2 diabetes. It also helps reduce the risk of hospitalization and death in adults with heart failure or chronic kidney disease. Entresto is taken twice daily, while Farxiga is taken once daily. Entresto is not available as a generic, whereas Farxiga has a lower-cost generic option. Common side effects of Entresto include low blood pressure and dizziness, while Farxiga may cause yeast infections, urinary tract infections, and increased urination. Entresto should not be taken with angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors, while Farxiga can interact with other diabetes medications and with diuretics.
Entresto (sacubitril / valsartan)
Farxiga (dapagliflozin)
Entresto (sacubitril / valsartan)
Farxiga (dapagliflozin)
Summary of Entresto vs. Farxiga
Summary for Angiotensin receptor-neprilysin inhibitor (ARNI)
Prescription only
Entresto (sacubitril / valsartan) is a combination medication called an angiotensin receptor-neprilysin inhibitor (ARNI). It's used for heart failure in adults and children ages 1 year and older. It helps lower the risk of hospital stays and heart-related death in adults with heart failure. You usually take the medication by mouth twice a day. Entresto is available as tablets. It also comes as Entresto Sprinkle, which are capsules you open and mix the pellets inside with soft food. Side effects include low blood pressure and cough. As of early 2025, there's no generic version of this medication.
Summary for SGLT2 inhibitor
Prescription only
Farxiga, the brand name for dapagliflozin, is used together with a nutritious diet and exercise plan to lower blood sugar levels in people 10 years and older with Type 2 diabetes. It can also help lower the risk of serious complications, hospitalization, and death in certain adults with heart failure or chronic kidney disease (CKD). Farxiga (dapagliflozin) belongs to the drug class called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It's taken by mouth once a day. Some side effects include yeast infections, urinating more often, and weight loss.
•Type 2 diabetes (in addition to diet and exercise) in people age 10 and over
•Lowering the risk of hospitalization for heart failure in adults with Type 2 diabetes and heart disease
•Lowering the risk of hospitalization and death due to heart problems in people with heart failure
•Lowering the risk of worsening kidney problems, hospitalization for heart failure, and death due to heart problems in adults with chronic kidney disease (CKD)
Pros and Cons of Entresto vs. Farxiga
Pros and Const for Angiotensin receptor-neprilysin inhibitor (ARNI)